James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the ability to treat patients.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.
S. Vincent Rajkumar, MD, of the Mayo Clinic, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss key issues in treating this disease, including monoclonal antibodies, plasmacytoma, and plasma cell leukemia.
Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relapsing/refractory disease.
